Recent advances in ADC technology have led to the development of several TROP2-targeting agents, including sacituzumab govitecan and datopotamab deruxtecan, which have demonstrated significant efficacy and acceptable safety in patients with advanced or treatment-resistant TNBC and ovarian carcinoma. The gene discussed is TACSTD2; the disease is ovarian carcinoma.